Report Detail
Global Hematologic Malignancies Treatment Market 2024 by Company, Regions, Type and Application, Forecast to 2030
- RnM4617477 |
- 26 September, 2024 |
- Global |
- 82 Pages |
- GIR (Global Info Research) |
- Other
Hematological malignancy, also known as hematological disease, is a type of cancer impacting bone marrow, blood, and lymph nodes. Different sorts of mature blood cells include white blood cells for immune protection, platelets for wound clotting, and red blood cells to carry oxygen. In the bone marrow, it originates from progenitor cells and hematopoietic stem. Hematologic malignancies initiate in these cells and are subcategorized as per the type of blood cell that is affected such as myeloid or myelogenous or and lymphocytic lymphoblastic. A malignancy in the lymphoid lineage involves B lymphocytes and T lymphocytes. Malignancy in the myeloid lineage involves precursor cells to white blood cells platelets and red blood cells.
According to our (Global Info Research) latest study, the global Hematologic Malignancies Treatment market size was valued at US$ 60710 million in 2023 and is forecast to a readjusted size of USD 247280 million by 2030 with a CAGR of 22.5% during review period.
Global key hematologic malignancies treatment manufacturers include Bristol-Myers Squibb, Johnson & Johnson, AbbVie etc. The top 3 company hold a share about 60%. North America is the largest market, with a share about 50%, followed by Europe and Asia-Pacific with the share both about 22%. In terms of product, chemotherapy is the largest segment, with a share over 30%. And in terms of application, the largest application is leukemia, followed by lymphoma and multiple myeloma.
This report is a detailed and comprehensive analysis for global Hematologic Malignancies Treatment market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Disease. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.
Key Features:
Global Hematologic Malignancies Treatment market size and forecasts, in consumption value ($ Million), 2019-2030
Global Hematologic Malignancies Treatment market size and forecasts by region and country, in consumption value ($ Million), 2019-2030
Global Hematologic Malignancies Treatment market size and forecasts, by Type and by Disease, in consumption value ($ Million), 2019-2030
Global Hematologic Malignancies Treatment market shares of main players, in revenue ($ Million), 2019-2024
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Hematologic Malignancies Treatment
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Hematologic Malignancies Treatment market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bristol-Myers Squibb, Johnson & Johnson, AbbVie, Novartis, Roche, Amgen, Takeda, Pfizer, AstraZeneca, Gilead Sciences, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Hematologic Malignancies Treatment market is split by Type and by Disease. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Disease. This analysis can help you expand your business by targeting qualified niche markets.
Market segmentation
Hematologic Malignancies Treatment market is split by Type and by Disease. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Disease. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Chemotherapy
Targeted Therapy
Immunotherapy
Market segment by Disease
Leukemia
Lymphoma
Multiple Myeloma
Others
Market segment by players, this report covers
Bristol-Myers Squibb
Johnson & Johnson
AbbVie
Novartis
Roche
Amgen
Takeda
Pfizer
AstraZeneca
Gilead Sciences
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Hematologic Malignancies Treatment product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Hematologic Malignancies Treatment, with revenue, gross margin, and global market share of Hematologic Malignancies Treatment from 2019 to 2024.
Chapter 3, the Hematologic Malignancies Treatment competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Disease, with consumption value and growth rate by Type, by Disease, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Hematologic Malignancies Treatment market forecast, by regions, by Type and by Disease, with consumption value, from 2024 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Hematologic Malignancies Treatment.
Chapter 13, to describe Hematologic Malignancies Treatment research findings and conclusion.
1 Market Overview
- 1.1 Product Overview and Scope
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Classification of Hematologic Malignancies Treatment by Type
- 1.3.1 Overview: Global Hematologic Malignancies Treatment Market Size by Type: 2019 Versus 2023 Versus 2030
- 1.3.2 Global Hematologic Malignancies Treatment Consumption Value Market Share by Type in 2023
- 1.3.3 Chemotherapy
- 1.3.4 Targeted Therapy
- 1.3.5 Immunotherapy
- 1.4 Global Hematologic Malignancies Treatment Market by Disease
- 1.4.1 Overview: Global Hematologic Malignancies Treatment Market Size by Disease: 2019 Versus 2023 Versus 2030
- 1.4.2 Leukemia
- 1.4.3 Lymphoma
- 1.4.4 Multiple Myeloma
- 1.4.5 Others
- 1.5 Global Hematologic Malignancies Treatment Market Size & Forecast
- 1.6 Global Hematologic Malignancies Treatment Market Size and Forecast by Region
- 1.6.1 Global Hematologic Malignancies Treatment Market Size by Region: 2019 VS 2023 VS 2030
- 1.6.2 Global Hematologic Malignancies Treatment Market Size by Region, (2019-2030)
- 1.6.3 North America Hematologic Malignancies Treatment Market Size and Prospect (2019-2030)
- 1.6.4 Europe Hematologic Malignancies Treatment Market Size and Prospect (2019-2030)
- 1.6.5 Asia-Pacific Hematologic Malignancies Treatment Market Size and Prospect (2019-2030)
- 1.6.6 South America Hematologic Malignancies Treatment Market Size and Prospect (2019-2030)
- 1.6.7 Middle East & Africa Hematologic Malignancies Treatment Market Size and Prospect (2019-2030)
2 Company Profiles
- 2.1 Bristol-Myers Squibb
- 2.1.1 Bristol-Myers Squibb Details
- 2.1.2 Bristol-Myers Squibb Major Business
- 2.1.3 Bristol-Myers Squibb Hematologic Malignancies Treatment Product and Solutions
- 2.1.4 Bristol-Myers Squibb Hematologic Malignancies Treatment Revenue, Gross Margin and Market Share (2019-2024)
- 2.1.5 Bristol-Myers Squibb Recent Developments and Future Plans
- 2.2 Johnson & Johnson
- 2.2.1 Johnson & Johnson Details
- 2.2.2 Johnson & Johnson Major Business
- 2.2.3 Johnson & Johnson Hematologic Malignancies Treatment Product and Solutions
- 2.2.4 Johnson & Johnson Hematologic Malignancies Treatment Revenue, Gross Margin and Market Share (2019-2024)
- 2.2.5 Johnson & Johnson Recent Developments and Future Plans
- 2.3 AbbVie
- 2.3.1 AbbVie Details
- 2.3.2 AbbVie Major Business
- 2.3.3 AbbVie Hematologic Malignancies Treatment Product and Solutions
- 2.3.4 AbbVie Hematologic Malignancies Treatment Revenue, Gross Margin and Market Share (2019-2024)
- 2.3.5 AbbVie Recent Developments and Future Plans
- 2.4 Novartis
- 2.4.1 Novartis Details
- 2.4.2 Novartis Major Business
- 2.4.3 Novartis Hematologic Malignancies Treatment Product and Solutions
- 2.4.4 Novartis Hematologic Malignancies Treatment Revenue, Gross Margin and Market Share (2019-2024)
- 2.4.5 Novartis Recent Developments and Future Plans
- 2.5 Roche
- 2.5.1 Roche Details
- 2.5.2 Roche Major Business
- 2.5.3 Roche Hematologic Malignancies Treatment Product and Solutions
- 2.5.4 Roche Hematologic Malignancies Treatment Revenue, Gross Margin and Market Share (2019-2024)
- 2.5.5 Roche Recent Developments and Future Plans
- 2.6 Amgen
- 2.6.1 Amgen Details
- 2.6.2 Amgen Major Business
- 2.6.3 Amgen Hematologic Malignancies Treatment Product and Solutions
- 2.6.4 Amgen Hematologic Malignancies Treatment Revenue, Gross Margin and Market Share (2019-2024)
- 2.6.5 Amgen Recent Developments and Future Plans
- 2.7 Takeda
- 2.7.1 Takeda Details
- 2.7.2 Takeda Major Business
- 2.7.3 Takeda Hematologic Malignancies Treatment Product and Solutions
- 2.7.4 Takeda Hematologic Malignancies Treatment Revenue, Gross Margin and Market Share (2019-2024)
- 2.7.5 Takeda Recent Developments and Future Plans
- 2.8 Pfizer
- 2.8.1 Pfizer Details
- 2.8.2 Pfizer Major Business
- 2.8.3 Pfizer Hematologic Malignancies Treatment Product and Solutions
- 2.8.4 Pfizer Hematologic Malignancies Treatment Revenue, Gross Margin and Market Share (2019-2024)
- 2.8.5 Pfizer Recent Developments and Future Plans
- 2.9 AstraZeneca
- 2.9.1 AstraZeneca Details
- 2.9.2 AstraZeneca Major Business
- 2.9.3 AstraZeneca Hematologic Malignancies Treatment Product and Solutions
- 2.9.4 AstraZeneca Hematologic Malignancies Treatment Revenue, Gross Margin and Market Share (2019-2024)
- 2.9.5 AstraZeneca Recent Developments and Future Plans
- 2.10 Gilead Sciences
- 2.10.1 Gilead Sciences Details
- 2.10.2 Gilead Sciences Major Business
- 2.10.3 Gilead Sciences Hematologic Malignancies Treatment Product and Solutions
- 2.10.4 Gilead Sciences Hematologic Malignancies Treatment Revenue, Gross Margin and Market Share (2019-2024)
- 2.10.5 Gilead Sciences Recent Developments and Future Plans
3 Market Competition, by Players
- 3.1 Global Hematologic Malignancies Treatment Revenue and Share by Players (2019-2024)
- 3.2 Market Share Analysis (2023)
- 3.2.1 Market Share of Hematologic Malignancies Treatment by Company Revenue
- 3.2.2 Top 3 Hematologic Malignancies Treatment Players Market Share in 2023
- 3.2.3 Top 6 Hematologic Malignancies Treatment Players Market Share in 2023
- 3.3 Hematologic Malignancies Treatment Market: Overall Company Footprint Analysis
- 3.3.1 Hematologic Malignancies Treatment Market: Region Footprint
- 3.3.2 Hematologic Malignancies Treatment Market: Company Product Type Footprint
- 3.3.3 Hematologic Malignancies Treatment Market: Company Product Application Footprint
- 3.4 New Market Entrants and Barriers to Market Entry
- 3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
- 4.1 Global Hematologic Malignancies Treatment Consumption Value and Market Share by Type (2019-2024)
- 4.2 Global Hematologic Malignancies Treatment Market Forecast by Type (2025-2030)
5 Market Size Segment by Disease
- 5.1 Global Hematologic Malignancies Treatment Consumption Value Market Share by Disease (2019-2024)
- 5.2 Global Hematologic Malignancies Treatment Market Forecast by Disease (2025-2030)
6 North America
- 6.1 North America Hematologic Malignancies Treatment Consumption Value by Type (2019-2030)
- 6.2 North America Hematologic Malignancies Treatment Market Size by Disease (2019-2030)
- 6.3 North America Hematologic Malignancies Treatment Market Size by Country
- 6.3.1 North America Hematologic Malignancies Treatment Consumption Value by Country (2019-2030)
- 6.3.2 United States Hematologic Malignancies Treatment Market Size and Forecast (2019-2030)
- 6.3.3 Canada Hematologic Malignancies Treatment Market Size and Forecast (2019-2030)
- 6.3.4 Mexico Hematologic Malignancies Treatment Market Size and Forecast (2019-2030)
7 Europe
- 7.1 Europe Hematologic Malignancies Treatment Consumption Value by Type (2019-2030)
- 7.2 Europe Hematologic Malignancies Treatment Consumption Value by Disease (2019-2030)
- 7.3 Europe Hematologic Malignancies Treatment Market Size by Country
- 7.3.1 Europe Hematologic Malignancies Treatment Consumption Value by Country (2019-2030)
- 7.3.2 Germany Hematologic Malignancies Treatment Market Size and Forecast (2019-2030)
- 7.3.3 France Hematologic Malignancies Treatment Market Size and Forecast (2019-2030)
- 7.3.4 United Kingdom Hematologic Malignancies Treatment Market Size and Forecast (2019-2030)
- 7.3.5 Russia Hematologic Malignancies Treatment Market Size and Forecast (2019-2030)
- 7.3.6 Italy Hematologic Malignancies Treatment Market Size and Forecast (2019-2030)
8 Asia-Pacific
- 8.1 Asia-Pacific Hematologic Malignancies Treatment Consumption Value by Type (2019-2030)
- 8.2 Asia-Pacific Hematologic Malignancies Treatment Consumption Value by Disease (2019-2030)
- 8.3 Asia-Pacific Hematologic Malignancies Treatment Market Size by Region
- 8.3.1 Asia-Pacific Hematologic Malignancies Treatment Consumption Value by Region (2019-2030)
- 8.3.2 China Hematologic Malignancies Treatment Market Size and Forecast (2019-2030)
- 8.3.3 Japan Hematologic Malignancies Treatment Market Size and Forecast (2019-2030)
- 8.3.4 South Korea Hematologic Malignancies Treatment Market Size and Forecast (2019-2030)
- 8.3.5 India Hematologic Malignancies Treatment Market Size and Forecast (2019-2030)
- 8.3.6 Southeast Asia Hematologic Malignancies Treatment Market Size and Forecast (2019-2030)
- 8.3.7 Australia Hematologic Malignancies Treatment Market Size and Forecast (2019-2030)
9 South America
- 9.1 South America Hematologic Malignancies Treatment Consumption Value by Type (2019-2030)
- 9.2 South America Hematologic Malignancies Treatment Consumption Value by Disease (2019-2030)
- 9.3 South America Hematologic Malignancies Treatment Market Size by Country
- 9.3.1 South America Hematologic Malignancies Treatment Consumption Value by Country (2019-2030)
- 9.3.2 Brazil Hematologic Malignancies Treatment Market Size and Forecast (2019-2030)
- 9.3.3 Argentina Hematologic Malignancies Treatment Market Size and Forecast (2019-2030)
10 Middle East & Africa
- 10.1 Middle East & Africa Hematologic Malignancies Treatment Consumption Value by Type (2019-2030)
- 10.2 Middle East & Africa Hematologic Malignancies Treatment Consumption Value by Disease (2019-2030)
- 10.3 Middle East & Africa Hematologic Malignancies Treatment Market Size by Country
- 10.3.1 Middle East & Africa Hematologic Malignancies Treatment Consumption Value by Country (2019-2030)
- 10.3.2 Turkey Hematologic Malignancies Treatment Market Size and Forecast (2019-2030)
- 10.3.3 Saudi Arabia Hematologic Malignancies Treatment Market Size and Forecast (2019-2030)
- 10.3.4 UAE Hematologic Malignancies Treatment Market Size and Forecast (2019-2030)
11 Market Dynamics
- 11.1 Hematologic Malignancies Treatment Market Drivers
- 11.2 Hematologic Malignancies Treatment Market Restraints
- 11.3 Hematologic Malignancies Treatment Trends Analysis
- 11.4 Porters Five Forces Analysis
- 11.4.1 Threat of New Entrants
- 11.4.2 Bargaining Power of Suppliers
- 11.4.3 Bargaining Power of Buyers
- 11.4.4 Threat of Substitutes
- 11.4.5 Competitive Rivalry
12 Industry Chain Analysis
- 12.1 Hematologic Malignancies Treatment Industry Chain
- 12.2 Hematologic Malignancies Treatment Upstream Analysis
- 12.3 Hematologic Malignancies Treatment Midstream Analysis
- 12.4 Hematologic Malignancies Treatment Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
- 14.1 Methodology
- 14.2 Research Process and Data Source
Summary:
Get latest Market Research Reports on Hematologic Malignancies Treatment. Industry analysis & Market Report on Hematologic Malignancies Treatment is a syndicated market report, published as Global Hematologic Malignancies Treatment Market 2024 by Company, Regions, Type and Application, Forecast to 2030. It is complete Research Study and Industry Analysis of Hematologic Malignancies Treatment market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
